Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Salivary Gland Cancer, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Salivary Gland Cancer, Salivary Gland Squamous Cell Carcinoma, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity and Tongue Cancer Clinical Trial Using laboratory biomarker analysis, placebo and afatinib

- The folks at Eastern Cooperative Oncology Group are studying the effects of afatinib; placebo; laboratory biomarker analysis on Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Salivary Gland Cancer, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Salivary Gland Cancer, Salivary Gland Squamous Cell Carcinoma, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity and Tongue Cancer in individuals ages 18 years and older. This clinical trial is slated to start July 2013.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence."

Locations

Eastern Cooperative Oncology Group

Boston, Massachusetts - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.